Results from the 5-year, phase IV RENEW (Registry to Evaluate Novantrone Effects in Worsening Multiple Sclerosis) study

BMC Neurology

Volumn 13, Issue , 2013, Pages

  Rivera, Victor M ^a   Jeffery, Douglas R ^b   Weinstock Guttman, Bianca ^c   Bock, Daena ^d   Dangond, Fernando ^d  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b Cornerstone Health Care ^*  (United States)

^c JACOBS NEUROLOGICAL INSTITUTE   (United States)

^d EMD SERONO INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOXANTRONE;

ADULT; AGED; AMENORRHEA; ARTICLE; CARDIOMYOPATHY; CARDIOPULMONARY INSUFFICIENCY; CARDIOTOXICITY; CONGESTIVE HEART FAILURE; DRUG MONITORING; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPOKINESIA; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; MENSTRUATION; MITRAL VALVE REGURGITATION; MULTICENTER STUDY; MULTIPLE SCLEROSIS; RISK FACTOR; TACHYCARDIA; URINARY TRACT INFECTION; CLINICAL TRIAL; HEART FAILURE; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PHASE 4 CLINICAL TRIAL; REGISTER; YOUNG ADULT;

ADULT; AGED; FEMALE; HEART FAILURE; HUMANS; LEUKEMIA; MALE; MIDDLE AGED; MITOXANTRONE; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; REGISTRIES; RISK FACTORS; YOUNG ADULT;

EID: 84880025390     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/1471-2377-13-80     Document Type: Article

References (41)

1. Levine S, Saltzman A. Regional suppression, therapy after onset and prevention of relapses in experimental allergic encephalomyelitis by Mitoxantrone. J Neuroimmunol 1986, 13:175-181. 10.1016/0165-5728(86)90063-9, 3491090.
2. Lublin FD, Lavasa M, Viti C, Knobler RL. Suppression of acute and relapsing experimental allergic encephalomyelitis with Mitoxantrone. Clin Immunol Immunopathol 1987, 45:122-128. 10.1016/0090-1229(87)90118-8, 3621681.
3. Watson CM, Davison AN, Baker D, O'Neill JK, Turk JL. Suppression of demyelination by Mitoxantrone. Int J Immunopharmacol 1991, 13:923-930. 10.1016/0192-0561(91)90045-9, 1761358.
4. Edan G, Miller D, Clanet M, Confavreux C, Lyon-Caen O, Lubetzki C, Brochet B, Berry I, Rolland Y, Froment JC, Cabanis E, Iba-Zizen MT, Gandon JM, Lai HM, Moseley I, Sabouraud O. Therapeutic effect of Mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997, 62:112-118. 10.1136/jnnp.62.2.112, 486720, 9048709.
5. Hartung HP, Gonsette R, König N, Kwiecinski H, Guseo A, Morrissey SP, Krapf H, Zwingers T. Mitoxantrone in Multiple Sclerosis Study Group (MIMS): Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002, 360:2018-2025. 10.1016/S0140-6736(02)12023-X, 12504397.
6. Avasarala JR, Cross AH, Clifford DB, Singer BA, Siegel BA, Abbey EE. Rapid onset Mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. Mult Scler 2003, 9:59-62. 10.1191/1352458503ms896oa, 12617270.
7. De-Castro CS, Cartoni D, Millefiorini E, Funaro S, Gasperini C, Morino S, Tallarico D, Beni S. Non-invasive assessment of mitoxantrone cardiotoxicity in relapsing remitting multiple sclerosis. J Clin Pharmacol 1995, 35:627-632. 10.1002/j.1552-4604.1995.tb05021.x, 7665724.
8. Ghalie RG, Edan G, Laurent M, Mauch E, Eisenman S, Hartung HP, Gonsette RE, Butine MD, Goodkin DE. Cardiac adverse effects associated with Mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002, 59:909-913. 10.1212/WNL.59.6.909, 12297576.
9. Hamzehloo A, Etemadifar M. Mitoxantrone-induced cardiotoxicity in patients with multiple sclerosis. Arch Iran Med 2006, 9:111-114.
10. Paul F, Dörr J, Würfel J, Vogel HP, Zipp F. Early Mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry 2007, 78:198-200. 10.1136/jnnp.2006.091033, 2077678, 17229751.
11. Zingler VC, Nabauer M, Jahn K, Gross A, Hohlfeld R, Brandt T, Strupp M. Assessment of potential cardiotoxic side effects of Mitoxantrone in patients with multiple sclerosis. Eur Neurol 2005, 54:28-33. 10.1159/000087242, 16088176.
12. Goffette S, van-Pesch V, Vanoverschelde JL, Morandini E, Sindic CJ. Severe delayed heart failure in three multiple sclerosis patients previously treated with Mitoxantrone. J Neurol 2005, 252:1217-1222. 10.1007/s00415-005-0839-3, 15834643.
13. Khatri BO, Wroblewski M, Kramer CJ, Dukic M, Poplar A, Anderson AJ. Mitoxantrone in worsening secondary progressive multiple sclerosis: a prospective, open-label study. CurrTher Res 2006, 67:55-65.
14. Ostberg A, Pittas F, V B. Use of low-dose Mitoxantrone to treat aggressive multiple sclerosis: a single-centre open-label study using patient self-assessment and clinical measures of multiple sclerosis status. Intern Med J 2005, 35:382-387. 10.1111/j.1445-5994.2005.00862.x, 15958106.
15. Buttinelli C, Clemenzi A, Borriello G, Denaro F, Pozzilli C, Fieschi C. Mitoxantrone treatment in multiple sclerosis: a 5-year clinical and MRI follow-up. Eur J Neurol 2007, 14:1281-1287. 10.1111/j.1468-1331.2007.01969.x, 17956449.
16. Arruda WO, Montú MB, de-Oliveira MS, Ramina R. Acute myeloid leukaemia induced by Mitoxantrone: case report. Arq Neuropsiquiatr 2005, 63:327-329. 10.1590/S0004-282X2005000200024, 16100984.
17. Bosca I, Pascual AM, Casanova B, Coret F, Sanz MA. Four new cases of therapy-related acute promyelocytic leukemia after Mitoxantrone. Neurology 2008, 71:457-458. 10.1212/01.wnl.0000324422.69067.e7, 18678830.
18. Brassat D, Recher C, Waubant E, Le-Page E, Rigal-Huguet F, Laurent G, Edan G, Clanet M. Therapy-related acute myeloblastic leukemia after Mitoxantrone treatment in a patient with MS. Neurology 2002, 59:954-955. 10.1212/WNL.59.6.954, 12297591.
19. Cattaneo C, Almici C, Borlenghi E, Motta M, Rossi G. A case of acute promyelocytic leukaemia following Mitoxantrone treatment of multiple sclerosis. Leukemia 2003, 17:985-986.
20. Delisse B, de-Seze J, Mackowiak A, N'Kendjuo JB, Verier A, Derepeer O, Boisselier C, Devos P, Hautecoeur P, Vermersch P. G-SEP Therapy related acute myeloblastic leukaemia after Mitoxantrone treatment in a patient with multiple sclerosis. Mult Scler 2004, 10:92. G-SEP.
21. Ellis R, Boggild M. Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it?. Mult Scler 2009, 15:505-508.
22. Ghalie RG, Mauch E, Edan G, Hartung HP, Gonsette RE, Eisenmann S, Le-Page E, Butine MD, De-Goodkin DE. A study of therapy-related acute leukaemia after Mitoxantrone therapy for multiple sclerosis. Mult Scler 2002, 8:441-445. 10.1191/1352458502ms836oa, 12356214.
23. Heesen C, Bruegmann M, Gbdamosi J, Koch E, Mönch A, Buhmann C. Therapy-related acute myelogenous leukaemia (t-AML) in a patient with multiple sclerosis treated with Mitoxantrone. Mult Scler 2003, 9:213-214.
24. Ledda A, Caocci G, Spinicci G, Cocco E, Mamusa E, La Nasa G. Two new cases of acute promyelocytic leukemia following Mitoxantrone treatment in patients with multiple sclerosis. Leukemia 2006, 20:2217-2218. 10.1038/sj.leu.2404443, 17051242.
25. Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW. Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology Evidence Report: The efficacy and safety of Mitoxantrone (Novantrone) in the treatment of multiple sclerosis: Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010, 74:1463-1470. 10.1212/WNL.0b013e3181dc1ae0, 2871006, 20439849, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.
26. Martinelli V, Cocco E, Capra R, Salemi G, Gallo P, Capobianco M, Pesci I, Ghezzi A, Pozzilli C, Lugaresi A, Bellantonio P, Amato MP, Grimaldi LM, Tojano M, Mancardi GL, Bergamaschi R, Gasperini C, Rodegher M, Straffi L, Ponzio M, Comi G. Italian Mitoxantrone Group Acute myeloid leukemia in Italian patients with multiple sclerosis treated with Mitoxantrone. Neurology 2011, 77:1887-1895. 10.1212/WNL.0b013e318238ee00, 22076543, Italian Mitoxantrone Group.
27. Novoselac AV, Reddy S, Sanmugarajah J. Acute promyelocytic leukemia in a patient with multiple sclerosis following treatment with Mitoxantrone. Leukemia 2004, 18:1561-1562. 10.1038/sj.leu.2403417, 15215874.
28. Pascual AM, Téllez N, Boscá I, Mallada J, Belenguer A, Abellán I, Sempere AP, Fernández P, Magraner MJ, Coret F, Sanz MA, Montalbán X, Casanova B. Revision of the risk of secondary leukaemia after Mitoxantrone in multiple sclerosis populations is required. Mult Scler 2009, 15:1303-1310. 10.1177/1352458509107015, 19825889.
29. Tanasescu R, Debouverie M, Pittion S, Anxionnat R, Vespignani H. Acute myeloid leukaemia induced by Mitoxantrone in a multiple sclerosis patient. J Neurol 2004, 251:762-763.
30. Vicari AM, Ciceri F, Folli F, Lanzi R, Colombo B, Comi G, Camba L. Acute promyelocytic leukemia following Mitoxantrone as single agent for the treatment of multiple sclerosis. Leukemia 1998, 12:441-442. 10.1038/sj.leu.2400915, 9529141.
31. Voltz R, Starck M, Zingler V, Strupp M, Kolb HJ. Mitoxantrone therapy in multiple sclerosis and acute leukaemia: a case report out of 644 treated patients. Mult Scler 2004, 10:472-474. 10.1191/1352458504ms1047cr, 15327049.
32. Woo DA, Collins RH, Rossman HS, Stüve O, Frohman EM. Mitoxantrone-associated leukemia in multiple sclerosis: case studies. Int J MS Care 2008, 10:41-46.
33. Le-Page E, Leray E, Edan G. French Mitoxantrone Safety Group Long-term safety profile of Mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study. Mult Scler 2011, 17:867-875. 10.1177/1352458511398371, 21325016, French Mitoxantrone Safety Group.
34. Myasoedova E, Gabriel SE. Cardiovascular disease in rheumatoid arthritis: a step forward. Curr Opin Rheumatol 2010, 22:342-347. 10.1097/BOR.0b013e3283379b91, 20164773.
35. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002, 359:1173-1177. 10.1016/S0140-6736(02)08213-2, 11955534.
36. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 2005, 44:677-680.
37. Myasoedova E, Crowson CS, Nicola PJ, Maradit-Kremers H, David JM, Roger VL, Therneau TM, Gabriel SE. The influence of rheumatoid arthritis disease characteristics on heart failure. J Rheumatol 2011, 38:1601-1606. 10.3899/jrheum.100979, 3337549, 21572155.
38. Greenberg JD, Kremer JM, Curtis JR. CORRONA Investigators Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011, 70:576-582. 10.1136/ard.2010.129916, 21109516, CORRONA Investigators.
39. Jadidi E, Mohammadi M, Moradi T. High risk of cardiovascular diseases after diagnosis of multiple sclerosis. Mult Scler 2013, Jan 30. [Epub ahead of print].
40. Fleming ST, Blake RL. Patterns of comorbidity in elderly patients with multiple sclerosis. J Clin Epidemiol 1994, 47:1127-1132. 10.1016/0895-4356(94)90099-X, 7722546.
41. Allen NB, Lichtman JH, Cohen HW, Fang J, Brass LM, Alderman MH. Vascular disease among hospitalized multiple sclerosis patients. Neuroepidemiology 2008, 30:234-238. 10.1159/000128103, 18437030.